- Report
- August 2024
- 100 Pages
Global
From €5418EUR$5,950USD£4,660GBP
- Report
- April 2025
- 200 Pages
Global
From €4089EUR$4,490USD£3,516GBP
- Report
- March 2025
- 180 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Report
- August 2024
- 85 Pages
United States
From €3187EUR$3,500USD£2,741GBP
- Report
- June 2023
- 115 Pages
Global
From €4098EUR$4,500USD£3,524GBP
- Report
- August 2022
- 30 Pages
Global
From €2504EUR$2,750USD£2,154GBP
- Report
- August 2023
- 217 Pages
Global
From €6830EUR$7,500USD£5,874GBP
- Report
- February 2024
- 106 Pages
Global
From €4326EUR$4,750USD£3,720GBP
Fabrazyme is a drug used to treat Fabry disease, a rare, inherited endocrine and metabolic disorder. It is a recombinant form of the enzyme alpha-galactosidase A, which is deficient in patients with Fabry disease. Fabrazyme helps to reduce the accumulation of a fatty substance called globotriaosylceramide (GL-3) in the body, which can lead to organ damage. Fabrazyme is administered intravenously and is available in two different doses.
Fabrazyme is marketed by Genzyme Corporation, a subsidiary of Sanofi, and is approved for use in the United States, Europe, Canada, Australia, and other countries. Other companies involved in the Fabrazyme market include Shire, Amicus Therapeutics, and Protalix BioTherapeutics. Show Less Read more
